MYC and diffuse large B-cell lymphoma: Although R/R DLBCL with c-Myc overexpression showed poor responses to selinexor, combination therapies with other novel drugs may induce responses, such as ibrutinib, fimepinostat (CUDC-907), which had shown promising clinical efficacies [216, 217].